国际妇产科学杂志 ›› 2020, Vol. 47 ›› Issue (2): 138-142.

• 综述 • 上一篇    下一篇

miR-375在宫颈癌中的研究进展

王卉,王文豪,郝敏   

  1. 030001 太原,山西医科大学第二医院妇产科
  • 收稿日期:2019-07-24 修回日期:2019-11-04 出版日期:2020-04-15 发布日期:2020-04-15
  • 通讯作者: 郝敏,E-mail:2yuanhaomin@163.com E-mail:2yuanhaomin@163.com
  • 基金资助:
    国家卫计委公益性行业科研专项(201402010);山西省重点研发计划项目(201803D31121);山西省卫生计生委科研课题(2018GW04)

Research Progress of miR-375 in Cervical Cancer

WANG Hui,WANG Wen-hao,HAO Min   

  1. Department of Obstetrics and Gynecology,Second Hospital of Shanxi Medical University,Taiyuan 030001,China
  • Received:2019-07-24 Revised:2019-11-04 Published:2020-04-15 Online:2020-04-15
  • Contact: HAO Min,E-mail:2yuanhaomin@163.com E-mail:2yuanhaomin@163.com

摘要: 宫颈癌是全球第四大最常见的女性恶性肿瘤,且呈年轻化趋势发展,因此早期诊断治疗非常重要。微小RNA(microRNA,miRNA)是由19~23个核苷酸组成的保守的单链非编码小分子RNA。miRNA被证实在许多人类恶性肿瘤中都异常表达,其在恶性肿瘤的发生、发展和转移中起着重要作用。miR-375作为一种高度保守的miRNA,存在于人类的2号染色体,被证实在宫颈癌患者中表达下调,其通过调控下游靶基因的表达,从而参与宫颈癌变的进展过程。血清miR-375的敏感度和特异度均优于传统肿瘤标志物CA125,敏感度优于薄层液基细胞学检测(TCT),miR-375有望成为宫颈癌早期诊断的新的标志物。miR-375可以调控宫颈癌放化疗的敏感性,可作为潜在的有效药物靶点。miR-375的表达缺失促进宫颈癌的发生,亦是促进患者临床分期进展或者复发风险上升的重要因素,miR-375可作为预测宫颈癌预后的生物学标志物。综述miR-375参与宫颈癌进展的机制及其在临床诊断治疗和预后方面的研究进展。

关键词: 微RNAs;, 宫颈肿瘤;, 宫颈上皮内瘤样病变;, 细胞增殖;, 细胞凋亡

Abstract: Cervical cancer is the forth most common female cancer in the world, and it is developing in a younger trend. Therefore, early diagnosis and treatment is very important. MicroRNAs (miRNAs) are conserved, single-stranded, non-coding small RNAs composed of 19-23 nucleotides. MiRNAs have been shown to be abnormally expressed in many human cancers, and they play an important role in the development, progression and metastasis of cancer. As a highly conserved miRNA, miR-375 is present on human chromosome 2 and has been shown to be down-regulated in cervical cancer patients. It is involved in the progression of cervical cancer by regulating the expression of downstream target genes. The sensitivity and specificity of serum miR-375 are superior to the traditional tumor marker CA125. The sensitivity is better than that of liquid-based cytology (TCT). MiR-375 is expected to be a new marker for early diagnosis of cervical cancer. MiR-375 can regulate the sensitivity of chemoradiotherapy for cervical cancer, and it can be used as a potential effective drug target. Loss of expression of miR-375 promotes the occurrence of cervical cancer, and it is also an important factor to promote the progression of clinical stage or the risk of recurrence. MiR-375 can be used as a biomarker for predicting the prognosis of cervical cancer. In this article, we focus on the mechanism of miR-375 in the progression of cervical cancer and its clinical diagnosis and prognosis.

Key words: MicroRNAs;, Uterine cervical neoplasms;, Cervical intraepithelial neoplasia;, Cell proliferation, Apoptosis

中图分类号: